Abstract
With respect to different new therapeutical principles in treating the disseminated prostate carcinoma, the question arises which position has the formerly ‘classical’ oestrogen therapy – especially the one with diethylstilbestrol-diphosphate (Honvan®). One aspect of this question is represented by the clinical results so far obtained with diethylstilbestrol-diphosphate which do, however, not consider non-clinical, e.g., biochemical, pharmacokinetic, or experimental aspects. The essential clinical results of the last 30 years will be critically summarized according to the literature. Special interest is focused on the high-dose initial therapy with diethylstilbestrol-diphosphate with regard to analgetic effects. Another point of special interest is the behaviour of prostate-specific antigen during therapy courses with diethylstilbestrol-diphosphate.